We collect data and report statistics on opioid, stimulant, and other substance use and their impact on health and well-being.

From 1999 to 2022, the number of drug overdose deaths among U.S. females increased from ***** in 1999 to ****** in 2022. Globally, drug use is a general problem. As of 2021, there were an estimated *** million global drug consumers and **** million drug addicts. Opioid use in the United States Among many demographics, drug overdose deaths continue to rise in the United States. Opioids are the most commonly reported substance in drug-related deaths. The number of drug-related deaths in the U.S. due to opioids has dramatically increased since the early 2000s. In 2017, then-President Donald Trump declared a national emergency over the opioid crisis in the United States. Since then, there have been joint efforts among various governmental departments to address the opioid crisis through education and outreach. Substance use treatment Substance abuse treatment is vital in reducing the number of drug overdose deaths in the United States. As of 2020, the state of California had the largest number of substance abuse treatment facilities . However, many states in the U.S. have less than 100 substance abuse treatment facilities.

The global Opioid Use Disorder Treatment Market represents a sale of USD 856.9 million in 2025.

Attribute	Details
Projected Value by 2025	USD 856.9 million

Detailed Market Share Analysis

Global Market Share	Industry Share (%)
Top 3 (Indivior, Alkermes, Johnson & Johnson)	41.0%
Rest of Top 5 (Teva Pharmaceuticals, Pfizer)	6.3%
Chinese Suppliers (Chongqing Pharmaceutical, Shanghai Pharmaceuticals, and Sinopharm and others.)	13.9%
Emerging and Regional Players	38.8%

Tier-Wise Industry Classification 2025

Tier	Market Share (%)
Tier 1 (Indivior, Alkermes, Johnson & Johnson, Teva Pharmaceutical Industries Ltd.)	40.9%
Tier 2 (Mallinckrodt Pharmaceuticals, Viatris Inc, Braeburn Pharmaceuticals, and others)	32.7%
Tier 3 (Emerging and Regional Players)	26.4%

In 2017, the cost of opioid use disorder in California was around 36.5 billion U.S. dollars. This statistic illustrates the cost of opioid use disorder cases in the United States in 2017, by state, in million U.S. dollars.

Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

The incident locations represented are approximated and not the actual location of the incident (or individuals residence). A computer generated randomized distance adjustment is applied to each incident location to ensure data are anonymous. This approximated location data is also shown on the dashboard.Interacting with the DashboardMay 2018 Update: Click on one of the charts to filter the displayed data and drop down options. You can select multiple chart elements at a time (i.e. select male for gender and January and February for month). To clear the filters and return to seeing all the data, click on the selected chart elements to remove them.Click on one or more values in drop down to filter the data shown in the display. To clear filters and return to seeing all of the data, click on selected values in the drop down to remove them. For the date filter, select and then delete the text. The map legend is accessible through the navigation in the upper right hand cornerUse the map selection tool in the upper left corner or the map to select calls in specific areas. The following documents what data are collected and why they are being collected. Additional variables will be added to the dashboard in the next phase.Opioid Abuse ProbableA call may be coded as “opioid abuse probable” for many reasons, such asAre there are any medical symptoms indicative of opioid abuse?Are there physical indicators on scene (i.e. drug paraphernalia, pill bottles, etc.)?Are there witnesses or patient statements made that point to opioid abuse?Is there any other evidence that opioid abuse is probable with the patient?“Opioid abuse probable” is determined by Tempe Fire Medical Rescue Department’s Emergency medical technicians and paramedics on scene at the time of the incident. Narcan/Naloxone Given“Narcan/Naloxone Given” refers to whether the medication Narcan/Naloxone was given to patients who exhibited signs or symptoms of a potential opioid overdose or to patients who fall within treatment protocols that require Narcan/Naloxone to be given. Narcan/Naloxone are the same medication with Narcan being the trade name and Naloxone being the generic name for the medication. Narcan is the reversal medication used by medical providers for opioid overdoses.Groups“Groups” are used to determine if there are specific populations that have an increase in opioid abuse. The student population at ASU was being examined for other purposes to determine ASU's overall call volume impact in Tempe. Data collection with the university is consistent with Fire Departments who provide service to the other PAC 12 universities. Since this data set was already being evaluated, it was included in the opioid data collection as well.The Veteran and Homeless Groups were established as demographic tabs to identify trends and determine needs in conjunction with the City of Tempe’s Veterans and Homeless programs. Since these data sets were being evaluated already, they were included in the opioid data collection as well.The “unknown” group includes incidents where a patient is unable to answer or refuses to answer the demographic questions. GenderPatient gender is documented as male or female when crews are able to obtain this information from the patient. There are some circumstances where this information is not readily determined and the patient is unable to communicate with our crews. In these circumstances, crews may document unknown/unable to determine.

West Virginia is currently the state with the highest drug overdose death rate in the United States, with ** deaths per 100,000 population in 2022. Although West Virginia had the highest drug overdose death rate at that time, California was the state where the most people died from drug overdose. In 2022, around ****** people in California died from a drug overdose. The main perpetrator Opioids account for the majority of all drug overdose deaths in the United States. Opioids include illegal drugs such as heroin, legal prescription drugs like oxycodone, and illicitly manufactured synthetic drugs like fentanyl. The abuse of opioids has increased in recent years, leading to an increased number of drug overdose deaths. The death rate from heroin overdose hit an all-time high of *** per 100,000 population in 2016 and 2017, but has decreased in recent years. Now, illicitly manufactured synthetic opioids such as fentanyl account for the majority of opioid overdose deaths in the United States. Opioid epidemic The sharp rise in overdose deaths from opioids have led many to declare the United States is currently experiencing an opioid epidemic or opioid crisis. The causes of this epidemic are complicated but involve a combination of a rise in dispensed prescriptions, irresponsible marketing from pharmaceutical companies, a lack of physician-patient communication, increased social acceptance of prescription drugs, and an increased supply of cheap and potent heroin on the streets.

This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).

Data Source: DC Office of the Chief Medical Examiner (OCME) and American Community Survey (ACS) 1-Year Estimates

Why This Matters

Opioid-related overdoses have been continuously rising since the late 1990s, with synthetic opioids (such as Tramadol or Fentanyl) being responsible for a sharp rise in opioid-related deaths since 2013.

Opioid Use Disorder (OUD) is treatable, and recovery is possible. Accessing treatment can help people regain their health and continue avoid the dangers associated with opioid misuse.

Several systemic inequities, including disparities in the treatment of mental health disorders, have led to Black individuals dying from opioid overdoses at a higher rate than white individuals.

The District Response

LIVE.LONG.DC (LLDC) is the District’s strategic plan to reduce opioid use, misuse, and related deaths. The plan provides a strategic framework that guides opioid work and investments.

The District does work to prevent, reduce the harm of, treat, and aid in the recovery of opioid use. This includes educational efforts, supplying Naloxone, no-cost rides to initial treatment appointments, and recovery support services.

The Interactive, Ward-specific map provides information about opioid use disorder and substance us disorder-related resources and services available in the District.

The European opioid use disorder market will reach USD 131.3 million by 2025 growing at 5.8% CAGR, 2025 to 2035. The primary catalysts for growth are the swiftly escalating rates of opioid addiction, largely attributed to the misuse of prescription medications and other narcotics.

Attributes	Details
Estimated Value (2025)	USD 131.3 million
Value-based CAGR (2025 to 2035)	5.8%

Country Analysis

Countries	CAGR
UK	4.5%
Germany	4.8%
Italy	3.7%
France	5.2%
Spain	5.1%
Rest of Europe	2.9%

Market Concentration

Vendor Tier	Tier 1
Key Vendors	Indivior, Alkermes, Pfizer
Market Share (%)	60%
Description	Global leaders offering MAT drugs such as buprenorphine, methadone, and extended-release naltrexone.

Vendor Tier	Tier 2
Key Vendors	Camurus, Accord Healthcare, Mundipharma
Market Share (%)	30%
Description	Regional players focusing on injectable therapies and combination treatments.

Vendor Tier	Tier 3
Key Vendors	Emerging startups and digital health providers
Market Share (%)	10%
Description	Innovators providing telehealth platforms and digital therapeutics to improve adherence and access.

• The global industry was valued at US$ 3.2 Bn in 2023
• It is expected to grow at a CAGR of 9.9% from 2024 to 2034 and reach US$ 8.8 Bn by the end of 2034

Opioid Use Disorders Market Overview

Attribute	Detail
Market Drivers	Rise in Incidence of Opioid Addiction Government & Non-Government Agencies Increasingly Focusing on Creation of Awareness

Regional Analysis of Opioid Use Disorders Market

Attribute	Detail
Leading Region	North America

Global Opioid Use Disorders Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 3.2 Bn
Market Forecast (Value) in 2034	US$ 8.8 Bn
Growth Rate (CAGR)	9.9%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Drug Type Buprenorphine Methodone Naltrexone Route of Administration Oral Parenteral Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	Indivior PLC Alkermes plc Orexo AB Titan Pharmaceuticals, Inc. Mallinckrodt Pharmaceuticals BioDelivery Sciences International, Inc. Viatris Inc. (Mylan N.V.) Hikma Pharmaceuticals plc Camurus AB
Customization Scope	Available Upon Request
Pricing	Available Upon Request

IntroductionCognitive dysfunction related to opioid use disorder (OUD) requires investigation of the interconnected network of cognitive domains through behavioral experiments and graph data modeling.MethodsWe conducted n-back, selective and divided attention, and Wisconsin card sorting tests and reconstructed the interactive cognitive network of subscales or domains for individuals who use opioids and controls to identify the most central cognitive functions and their connections using graph model analysis. Each two subscales with significant correlations were connected by an edge that incorporated in formation of interactive networks. Each network was analyzed topologically based on the betweenness and closeness centrality measures.ResultsResults from the network reconstructed for individuals who use opioids show that in the divided attention module, reaction time and number of commission errors were the most central subscales of cognitive function. Whereas in controls, the number of correct responses and commission errors were the most central cognitive measure. We found that the subscale measures of divided attention module are significantly correlated with those of other tests. These findings corroborate that persons who use opioids show impaired divided attention as higher reaction time and errors in performing tasks. Divided attention is the most central cognitive function in both OUD subjects and controls, although differences were observed between the two groups in various subscales.DiscussionAlthough equal proportions of males and females may be used in future studies, divided attention and its subscales may be the most promising target for cognitive therapies, treatments and rehabilitation as their improvement can enhance overall cognitive domain performance.

The opioid abuse epidemic is a growing concern and has far reaching effects on society. Government agencies are addressing opioid abuse in various ways. This story map application introduces key facts about the opioid abuse crisis and provides related data and resources for getting help and preventing opioid medication misuse.Story Content Includes:What is the Opioid Abuse Epidemic?What are Opioids?History of the EpidemicThe Science of AddictionWhat is the Role of Heroin and Fentanyl in the Opioid Crisis? ​A National Epidemic and Local CrisisThe City of TempeRisk FactorsSigns and Symptoms of Opioid AbuseNaloxone Distribution LocationsDrug Drop Off LocationsTreatment ResourcesRemember those We've LostResources & Acknowledgements

In 2017, there were around 165,000 estimated cases of opioid use disorder in California. This statistic illustrates the estimated number of opioid use disorder cases in the United States in 2017, by state.

This dataset contains opioid-related deaths by age group. Opioid-related deaths include heroin and opioid analgesics mortalities.

Individuals misusing opioids often report heightened feelings of loneliness and decreased ability to maintain social connections. This disruption in social functioning further promotes addiction, creating a cycle in which increasing isolation drives drug use. Social factors also appear to impact susceptibility and progression of opioid dependence. In particular, increasing evidence suggests that poor early social bond formation and social environments may increase the risk of opioid abuse later in life. The brain opioid theory of social attachment suggests that endogenous opioids are key to forming and sustaining social bonds. Growing literature describes the opioid system as a powerful modulator of social separation distress and attachment formation in rodents and primates. In this framework, disruptions in opioidergic signaling due to opioid abuse may mediate social reward processing and behavior. While changes in endogenous opioid peptides and receptors have been reported in these early-life adversity models, the underlying mechanisms remain poorly understood. This review addresses the apparent bidirectional causal relationship between social deprivation and opioid addiction susceptibility, investigating the role of opioid transmission in attachment bond formation and prosocial behavior. We propose that early social deprivation disrupts the neurobiological substrates associated with opioid transmission, leading to deficits in social attachment and reinforcing addictive behaviors. By examining the literature, we discuss potential overlapping neural pathways between social isolation and opioid addiction, focusing on major reward-aversion substrates known to respond to opioids.

The point-of-care opioid testing market size is projected to be worth US$ 450.9 million in 2023. The market is likely to surpass US$ 725.1 million by 2033 at a CAGR of 4.9% during the forecast period. The market for point-of-care opioid testing has been experiencing substantial growth and is expected to continue expanding. The increasing prevalence of opioid abuse, the opioid crisis, and the need for immediate and accurate detection are the key drivers of this market growth. The market size is influenced by factors such as regional variations in opioid abuse rates, regulatory policies, and healthcare infrastructure.

Attributes	Details
Point-of-Care Opioid Testing Market Size (2023)	US$ 450.9 million
Point-of-Care Opioid Testing Market Projected Size (2033)	US$ 725.1 million
Value CAGR (2023 to 2033)	4.9%

Country-Wise Insights

Country	The United States
Market Size (US$ million) by End of Forecast Period (2033)	US$ 227.4 million
CAGR % 2023 to End of Forecast (2033)	4.2%

Country	The United Kingdom
Market Size (US$ million) by End of Forecast Period (2033)	US$ 32.0 million
CAGR % 2023 to End of Forecast (2033)	4.3%

Country	China
Market Size (US$ million) by End of Forecast Period (2033)	US$ 54.7 million
CAGR % 2023 to End of Forecast (2033)	6.4%

Country	Japan
Market Size (US$ million) by End of Forecast Period (2033)	US$ 39.9 million
CAGR % 2023 to End of Forecast (2033)	6.2%

Country	South Korea
Market Size (US$ million) by End of Forecast Period (2033)	US$ 45.4 million
CAGR % 2023 to End of Forecast (2033)	6.0%

Annual change of PC rate and risk factors.

BackgroundOpioids are often prescribed for pain relief, yet they pose risks such as addiction, dependence, and overdose. Pregnant women have unique vulnerabilities to opioids and infants born to opioid-exposed mothers could develop neonatal opioid withdrawal syndrome (NOWS). The study of opioid-induced epigenetic changes in chronic pain is in its early stages. This study aimed to identify epigenetic changes in genes associated with chronic pain resulting from maternal opioid exposure during pregnancy.MethodsWe analyzed DNA methylation of chronic pain-related genes in 96 placental tissues using Illumina Infinium Methylation EPIC BeadChips. These samples comprised 32 from mothers with infants prenatally exposed to opioids who needed pharmacologic NOWS management (+Opioids/+NOWS), 32 from mothers with prenatally opioid-exposed infants not needing NOWS pharmacologic treatment (+Opioids/-NOWS), and 32 from unexposed control subjects (-Opioids/-NOWS).ResultsThe study identified significant methylation changes at 111 CpG sites in pain-related genes among opioid-exposed infants, with 54 CpGs hypomethylated and 57 hypermethylated. These genes play a crucial role in various biological processes, including telomere length regulation (NOS3, ESR1, ESR2, MAPK3); inflammation (TNF, MAPK3, IL1B, IL23R); glucose metabolism (EIF2AK3, CACNA1H, NOTCH3, GJA1); ion channel function (CACNA1C, CACNA1H, CLIC4, KCNQ5); autophagy (CTSS, ULK1, ULK4, ATG5); oxidative stress (NGF, NRG1, OPRM1, ATP1A2); aging (GRIA1, NGFR, PRLR, EIF4E); cytokine activity (TRPV4, RUNX1, CXCL8, IL18R1); and the risk of suicide (ADORA2A, ANKK1, GABRG2, IGSF9B). These epigenetic changes may influence 48 signaling pathways—including cAMP, MAPK, GnRH secretion, estrogen signaling, morphine addiction, circadian rhythms, and insulin secretion—profoundly affecting pain and inflammation-related processes.ConclusionThe identified methylation alterations may shed light on pain, neurodevelopmental changes, and other biological mechanisms in opioid-exposed infants and mothers with OUD, offering insights into NOWS and maternal-infant health. These findings may also pave the way for targeted interventions and improved pain management, highlighting the potential for integrated care strategies to address the interconnected health of mothers and infants.

The Centers for Medicare & Medicaid Services (CMS) has prepared a public data set, the Medicare Part D Opioid Prescriber Summary File, which presents information on the individual opioid prescribing rates of health providers that participate in Medicare Part D program. This file is a prescriber-level data set that provides data on the number and percentage of prescription claims (includes new prescriptions and refills) for opioid drugs, and contains information on each provider’s name, specialty, state, and ZIP code. This summary file was derived from the 2015 Part D Prescriber Summary Table (Documentation available at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Downloads/Prescriber_Methods.pdf